IL311917A - Methods for Inducing Hemodynamic Change by Administering an Anti-NPR1 Antibody - Google Patents
Methods for Inducing Hemodynamic Change by Administering an Anti-NPR1 AntibodyInfo
- Publication number
- IL311917A IL311917A IL311917A IL31191724A IL311917A IL 311917 A IL311917 A IL 311917A IL 311917 A IL311917 A IL 311917A IL 31191724 A IL31191724 A IL 31191724A IL 311917 A IL311917 A IL 311917A
- Authority
- IL
- Israel
- Prior art keywords
- effecting
- administering
- methods
- hemodynamic change
- npr1 antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163254447P | 2021-10-11 | 2021-10-11 | |
| PCT/US2022/077908 WO2023064769A1 (en) | 2021-10-11 | 2022-10-11 | Methods of effecting a hemodynamic change by administering an anti-npr1 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311917A true IL311917A (en) | 2024-06-01 |
Family
ID=84045029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311917A IL311917A (en) | 2021-10-11 | 2022-10-11 | Methods for Inducing Hemodynamic Change by Administering an Anti-NPR1 Antibody |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20240327539A1 (https=) |
| EP (1) | EP4415820A1 (https=) |
| JP (1) | JP2024537284A (https=) |
| KR (1) | KR20240099275A (https=) |
| CN (1) | CN118159290A (https=) |
| AU (1) | AU2022363841A1 (https=) |
| CA (1) | CA3234238A1 (https=) |
| CL (1) | CL2024001071A1 (https=) |
| CO (1) | CO2024005662A2 (https=) |
| IL (1) | IL311917A (https=) |
| MX (1) | MX2024004302A (https=) |
| WO (1) | WO2023064769A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313265A (en) | 2021-12-06 | 2024-08-01 | Regeneron Pharma | Antagonistic antibodies against NPR1 and methods of using them |
| WO2024251255A1 (zh) * | 2023-06-08 | 2024-12-12 | 江苏恒瑞医药股份有限公司 | 抗npr1抗体及其医药用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US9090695B2 (en) | 2008-12-03 | 2015-07-28 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
| MY205168A (en) | 2018-10-23 | 2024-10-04 | Regeneron Pharma | Anti-npr1 antibodies and uses thereof |
| EA202193345A1 (ru) * | 2019-06-12 | 2022-03-16 | Новартис Аг | Антитела к рецептору-1 натрийуретического пептида и способы их применения |
| US12325752B2 (en) * | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
-
2022
- 2022-10-11 IL IL311917A patent/IL311917A/en unknown
- 2022-10-11 EP EP22798040.6A patent/EP4415820A1/en active Pending
- 2022-10-11 CN CN202280068577.9A patent/CN118159290A/zh active Pending
- 2022-10-11 CA CA3234238A patent/CA3234238A1/en active Pending
- 2022-10-11 WO PCT/US2022/077908 patent/WO2023064769A1/en not_active Ceased
- 2022-10-11 US US18/045,671 patent/US20240327539A1/en not_active Abandoned
- 2022-10-11 MX MX2024004302A patent/MX2024004302A/es unknown
- 2022-10-11 AU AU2022363841A patent/AU2022363841A1/en active Pending
- 2022-10-11 KR KR1020247015704A patent/KR20240099275A/ko active Pending
- 2022-10-11 JP JP2024521784A patent/JP2024537284A/ja active Pending
-
2024
- 2024-04-10 CL CL2024001071A patent/CL2024001071A1/es unknown
- 2024-04-30 CO CONC2024/0005662A patent/CO2024005662A2/es unknown
- 2024-10-11 US US18/913,899 patent/US20250034279A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023064769A1 (en) | 2023-04-20 |
| AU2022363841A1 (en) | 2024-03-28 |
| US20240327539A1 (en) | 2024-10-03 |
| MX2024004302A (es) | 2024-06-19 |
| CL2024001071A1 (es) | 2024-12-06 |
| KR20240099275A (ko) | 2024-06-28 |
| CA3234238A1 (en) | 2023-04-20 |
| CO2024005662A2 (es) | 2024-05-10 |
| US20250034279A1 (en) | 2025-01-30 |
| EP4415820A1 (en) | 2024-08-21 |
| JP2024537284A (ja) | 2024-10-10 |
| CN118159290A (zh) | 2024-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL311917A (en) | Methods for Inducing Hemodynamic Change by Administering an Anti-NPR1 Antibody | |
| GB201915444D0 (en) | Method of using a blockchain | |
| IL288825A (en) | Methods for producing anti-alpha4 antibody in cell7 | |
| PL3924988T3 (pl) | Sposób produkcji korpusu spiralnego ze ściskaniem spirali | |
| IL284789A (en) | Immunoglobulin a antibodies and methods of production and use | |
| GB201901576D0 (en) | Production of 3C library | |
| IL286306A (en) | Manufacturing methods for producing anti-tnf antibody compositions | |
| PL3620059T3 (pl) | Sposób wytwarzania proszku spożywczego, korzystnie wegańskiego, na bazie mączki migdałowej | |
| GB201902908D0 (en) | Method of using a blockchain | |
| IL279528A (en) | A method for producing a controlled mixture of two or more different antibodies | |
| IL285984A (en) | Method for producing influenza ha split vaccine | |
| EP4163301A4 (en) | HUMANIZED ANTI-GPC-1 ANTIBODY | |
| GB202210334D0 (en) | Methods of production of aginine-silicate complexes | |
| IL290825A (en) | Methods of producing antibody compositions | |
| HK40110421A (en) | Methods of effecting a hemodynamic change by administering an anti-npr1 antibody | |
| IL289634A (en) | Novel reprogramming method | |
| IL280904A (en) | Method for manufacturing cyclopropane compound | |
| EP3941907A4 (en) | FIPRONIL SYNTHESIS METHOD | |
| GB201809783D0 (en) | A method of producing a structure | |
| IL290300A (en) | Novel composition comprising antibodies | |
| IL283678A (en) | Process for preparing bicyclic enolether | |
| EP3749367A4 (en) | USING THE GHR-106 MONOCLONAL ANTIBODY AS A GNRH ANTAGONIST | |
| EP4363455A4 (en) | METHOD OF ADMINISTRATION OF ANTI-HPA-1A MONOCLONAL ANTIBODY | |
| PL3822054T3 (pl) | Sposób produkcji płyty fornirowanej | |
| HK40085332A (en) | A transducer for producing vibrational movement |